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Summary Mechanisms for improving photodynamic therapy (PDT) were investigated in the murine RIFI
tumour using meso-tetrahydroxyphenylchlorin (m-THPC) or bacteriochlorin a (BCA) as photosensitisers and
comparing these results with Photofrin-mediated PDT. The 86Rb extraction technique was used to measure
changes in perfusion at various times after interstitial PDT. Non-curative combinations of light doses with
m-THPC and BCA PDT markedly decreased vascular perfusion. This decrease was more pronounced for both
new photosensitisers than for Photofrin. Comparison of tumour perfusion after PDT with tumour response
revealed an inverse correlation for all three photosensitisers, but the relationship was less clear for m-THPC
and BCA. In vivo/in vitro experiments were performed after Photofrin or m-THPC PDT in order to assess
direct tumour kill (immediate plating) vs indirect vascular effects (delayed plating). For both photosensitisers,
there was little direct cell killing but clonogenic survival decreased as the interval between treatment and
excision increased. When m-THPC PDT was combined with mitomycin C (MMC), light doses could be
decreased by a factor of 2 for equal tumour effects. Lower light and m-THPC doses could be used compared
with Photofrin PDT in combination with MMC. BCA PDT with MMC did not result in a greater tumour
response compared with BCA PDT alone. Reduction in both light and photosensitiser doses for effective PDT
regimes in combination with MMC offers substantial clinical advantages, since both treatment time and skin
photosensitisation will be reduced.
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Photodynamic therapy (PDT) has proved to be a useful
treatment for several types of solid cancers in man. The
photosensitiser currently in most widespread clinical use is
Photofrin, of which the major adverse side-effect is accu-
mulation of sensitiser in the skin, resulting in photosensitisa-
tion which can persist for 6-8 weeks (Dougherty et al.,
1990). Several new photosensitising agents have been
developed, aiming at reduced skin photosensitisation, along
with greater light absorbance at longer wavelengths. Meso-
tetrahydroxyphenylchlorin (m-THPC), absorption peak at
652 nm, has demonstrated excellent anti-tumour activity for
low doses of both drug and light (Ris et al., 1991, 1993; Van
Geel et al., 1995). Large gains were seen for m-THPC-
mediated PDT in tumours compared with Photofrin, plus
more rapid fading of skin photosensitisation. Bacteriochlorin
a (BCA), a derivative of bacteriochlorophyll a, has also
proven to be a very effective photosensitiser in vitro and in
vivo (Schuitmaker et al., 1990). BCA has a major absorption
peak at 760 nm, where tissue penetration is optimal. The
penetration depth of light used to activate this photosen-
sitiser, and thus the treated tumour volume, may therefore be
maximised.
Tumour damage by PDT occurs either by direct tumour
cell killing or, more importantly, by secondary cell killing
effects induced after severe vascular damage and ischaemia
(Henderson et al., 1985). This phenomenon of vascular
damage and induced hypoxia (Moore et al., 1993) occurring
at very short intervals following treatment led to the use of
PDT in conjunction with bioreductive drugs, which are
specifically toxic to hypoxic cells. Such studies have demon-
strated that PDT in combination with bioreductive drugs can
give enhanced anti-tumour effect (Gonzalez et al., 1986;
Bremner et al., 1992; Baas et al., 1994).
The purpose of this study was to measure the influence of
m-THPC- or BCA-mediated PDT on the vascular perfusion
and tumour response (regrowth time, cures and in vitro cell
survival) in subcutaneous RIFI tumours after in vivo PDT
and to compare these results with Photofrin-mediated PDT.
The vascular perfusion data were also required as a rational
basis for the development of protocols involving combined
PDT with the bioreductive agent mitomycin C (MMC).
Materials and methods
Animal models
All experiments were carried out in accordance with pro-
tocols approved by the local experimental animal welfare
committee and conform to national and European regula-
tions for animal experimentation. Female C3H/Km mice
were used in all experiments, weighing 21-30 g at an age of
11-16 weeks. Approximately 1 x I05 RIFI cells (maintained
and passaged according to recommended in vivo/in vitro pro-
tocols described by Twentyman et al., 1980) were inoculated
subcutaneously on the lower dorsum of mice, which were
briefly anaesthetised with enflurane. Tumour growth was
documented three times weekly by calliper measurements in
three orthogonal diameters. PDT was given 10-21 days after
inoculation when the tumour reached a diameter of 5-6 mm.
The tumours were free of evident necrosis at these sizes. The
tumour response to PDT was determined by the number of
cures or by regrowth time. Cures were defined as no visible
or palpable evidence of tumour at 90 days. Tumour regrowth
time was calculated as the time taken to regrow from treat-
ment size T to mean geometric diameter T + 2 mm. Mice
were sacrificed when tumours had reached a mean diameter
of >10 mm. A minimum of six mice per dose group were
treated.
Interstitial photodynamic therapy of tumours
The mice were injected i.v. with m-THPC (supplied by Scotia
Pharmaceuticals, UK) or BCA (synthesised, purified and sup-
plied by Dr Schuitmaker; Schuitmaker et al., 1990). m-THPC
was dissolved in 30% polyethylene glycol 400 (PEG), 20%
ethanol and 50% water at a concentration of 0.03-0.06
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March 1995mg ml-' (for doses of 0.15-0.3 mg kg-'). BCA was dissolved
in 3 ml of methanol: 10% Cremophor EL (Sigma, St Louis,
MO, USA) and 3% 1,2-propanediol were added. Thereafter
the methanol was evaporated under reduced pressure and
finally the mixture was diluted with sterile 0.9% saline. The
final concentration was 4.5 mg ml-' and doses of 20 mgkg-'
were administered. Photofrin (supplied by Quadra Logic
Technologies, Vancouver, Canada) was dissolved in 5% dext-
rose at a concentration of 2mgml-' for a dose of 10mg
kg-'. Photofrin was injected i.p. for the estimates of cell
survival after in vivo PDT, since previous experiments for
tumour response studies were carried out with i.p. injections.
However, no difference in tumour response was seen for
Photofrin (10 mg kg-') administered i.v. or i.p. at 1 day
before illumination (Van Geel et al., 1995). The photosen-
sitisers were injected 15 min (BCA), 1 h (BCA and m-THPC)
or 1 day (m-THPC and Photofrin) before illumination; time
intervals were chosen based on previous studies indicating
times of maximum drug uptake and photosensitisation (Table
I). Separate groups of control mice received BCA or m-
THPC alone (Table II). The bioreductive drug mitomycin C
(Kyowa, Japan) was administered in doses which caused
minimal acute toxicity, i.e. less than 5% weight loss. The
drug was dissolved in sterile water to a concentration of
0.5mgml-'. Doses of 5mgkg-' were given i.p. 15min
before illumination, or immediately after illumination; con-
trol groups receiving MMC alone, MMC in combination
with BCA or m-THPC or MMC plus illumination were also
included (Table II).
For m-THPC and Photofrin PDT, the light source was a
dye laser (Spectra Physics model 373) pumped by a 12W
argon laser (Spectra Physics model 171). Sulphorhodamine B
(Radiant Dyes Chemie, Wermelkirchen, Germany) was used
as the dye to obtain red laser light (mono Chromator Oriel
model 77320) of 628 ± 3 nm (Photofrin) or 652 ± 3 nm (m-
THPC). The light was directed to a beam splitter that equally
divided the light among four outputs, to which non-scin-
tillating polystyrene fibres (Bicron BCF, 1 mm outer
diameter) with 1 cm cylindrical diffusing tips were attached.
The output from each fibre was adjusted to 100 mWcm-'
and energies of 15-180 J cm-' were delivered, by varying the
exposure time from 2.5 to 30 min, at 1 h or 1 day after
mTHPC. Light alone controls were also treated (Table II).
For tumour illuminations, the diffusing fibre tips were
inserted through the centre ofthe tumours of unanaesthetised
mice held in restraining jigs, as described by Baas et al.
(1993).
For BCA-PDT a pigtailed (fibre diameter 100 Lm multi-
mode) diode laser (Philips), lasing at 750 nm maximum (out-
put 200mW), was used (Best et al., 1993). Light from the
diode laser was coupled into a 400lm multimode fibre with
1 cm cylindrical diffusing tip (1.25 mm outer diameter, QLT
Phototherapeutics, NY, USA). This multimode fibre was
used because the coupling of this fibre was more efficient for
this experimental set-up than coupling of a non-scintillating
polystyrene fibre. Light doses of 0-400 Jcm-' were delivered
at 15 min or 1 h after BCA. Light-alone controls were also
included at the 750 nm wavelength (Table II). Mice were kept
in subdued light for 2 weeks after receiving the photosen-
sitisers.
86RbCl extraction estimatesfor vascularperfusion
Vascular perfusion relative to the cardiac output was
measured using the 86RbCl extraction technique (Van Geel et
al., 1994). Each mouse was injected via the tail vein at 5 min
to 5 days after PDT with 0.1 ml of a rubidium chloride
solution (specific activity 1-8 mCimg-', from Amersham,
Aylesbury, UK}, which had been diluted with saline (0.9%)
to an activity of approximately I00 lCiml-'. After 1 min,
the mice were killed by cervical dislocation. The tumour,
kidney (control organ) and the tail were then removed and
the weighed samples counted in a gamma counter (Packard
Delft, The Netherlands, Minaxi Autogamma 5000 series) for
50 min (according to the expected level of activity) together
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Table I Photosensitisation and tumour uptake after injection of
Photofrin, m-THPC and BCA
Regrowth time
TP (days)b/light dose
(h) Tumour uptake (Jcm-')
g g-IC
Photofrin 6 2.7 ± 0.3 16.7 + 1.5/200
24 3.0± 0.3 16.0 0.9/200
72 2.4 ± 0.5 15.7 ± 0.9/240
% inj g)ld
m-THPC 1 0.5 ± 0.1 e/150
24 0.8 ± 0.2 22.9 2.1/150
72 1.1 ± 0.4 9.1 0.4/150
Fluorescencef
BCA 0.25 -125 17.5 5.6/150
1 -120 9.8 1.4/150
2 -80 -/150
aTI, time interval between photosensitiser and illumination.
b10 mgkg-' Photofrin (Baas et al., 1994); 0.15 mgkg-' m-THPC
(Van Geel et al., 1995) and 20mg kg-' BCA (present results).
CSpectrofluorometry measurements; RIFI mouse tumours (Van Geel
et al., 1994). d[I4C]m-THPC uptake in RIFI mouse tumours (Van
Geel et al., unpublished). eLethal toxicity. fFluorescence
measurements based on image analysis of grey scale values 0-200;
RMA rat tumours (Van Leengoed et al., 1993).
Table II Tumour regrowth times in the control groups
Regrowth time
Treatment (days)
Untreated control 2.8 ± 0.1
m-THPC (0.3 mgkg-') 4.5 0.5a
BCA (30 mg kg-') 4.4 ± 0.3a
MMC (5 mg kg-') 7.3 ± 0.3a
m-THPC (0.3 mg kg-') + MMC (5 mg kg-') 7.2 ± 0.7a
BCA (20 mg kg-') + MMC (5 mg kg-') 6.4 ± 0.6a
Light alone (A=652 nm: 60 J cm-') 3.8 ± 0.2a
Light alone (A= 750 nm: 300 J cm-') 4.5 ± 0.Sa
MMC + light (A=652 nm: 60 J cm-') 7.6 ± 0.8a
MMC + light (A=750 nm: 200 J cm-') 5.0 ± 0.3a
aSignificantly different from untreated control group (P<0.01).
with a 0.1 ml aliquot of the injection solution which was used
as a standard. Four to six mice per group were used for these
experiments. The tails were excised to check the residual
activity at the site of the injection (5-10% of the injected
dose in most mice) and the sample counts were corrected for
radioactivity in the tail before calculating the percentage of
injected dose in tumour or kidney. If the residual activity in
the tail was 15% or more, the samples were excluded from
analysis. Control groups receiving sensitiser alone, light alone
(652 and 750 nm) or no treatment were also tested for
tumour perfusion (Table III).
In vivo/in vitro assay
Tumours treated with Photofrin PDT or m-THPC PDT and
control tumours treated with photosensitiser alone, light
alone, MMC alone or receiving no treatment (Table IV) were
excised under sterile conditions after cervical dislocation.
Two tumours were pooled for each time point. For BCA
PDT no in vivo/in vitro assays were performed because with
this experimental set-up only one mouse could be treated per
time point. The excised tumours were protected from direct
light exposure, weighed, minced with scissors and placed into
a flask containing protease (type IX), DNAse (type I) and
collagenase (type IV) in 5 ml of sterile phosphate-buffered
saline (PBS) and stirred at 37'C for 30 min to release tumour
cells. The resulting suspension was then strained through a
wire mesh to eliminate any remaining tissue clumps and cell
aggregates. The cells were washed with Ham's F-10 medium
containing antibiotics (penicillin 100 IU ml-' and strepto-
mycin 100 g ml-') without serum and centrifuged for 5 minMechanisms foroptimising PDT
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at 1000 r.p.m. The supernatant was discarded and the cell
pellet resuspended in 10 ml of Ham's F-10 medium contain-
ing antibiotics and 10% fetal calf serum. Cell numbers were
determined with a Coulter counter, and after staining with
trypan blue the percentage of dead cells was counted with a
haemocytometer. Known numbers of viable cells were plated
into Petri dishes at appropriate concentrations in Ham's F-10
medium containing antibiotics and 10% fetal calf serum for
colony formation. After 6 days in a humidified 5% carbon
dioxide incubator at 37°C, the cells were washed with saline
(0.9%) and fixed and stained with glutaraldehyde (15%, w/w)
and crystal violet (2%, w/w). Colonies containing >50 cells
were then counted. The Coulter counter and haemocytometer
counts yielded information from which viable cell yield per
gram of tumour was calculated on the basis of total cell
counts. Colony assays were used to determine the fraction of
viable cells which were clonogenic. The combination was
used to calculate the yield of surviving cells per gram of
tumour.
Statistical analysis
Means and standard error of the means (s.e.m.) were cal-
culated for tumour regrowth times for each treatment group.
The cures were not included in the estimates of mean re-
growth time but were analysed separately. The TCD50 and
standard errors (± s.e.) (light dose required to cure 50%
tumours) were calculated by probit analysis. For the in vivol
in vitro studies mean and s.e. were calculated.
The significance of difference in vascular perfusion and
clonogenicities for the control groups and treated groups was
determined according to the non-parametric Kruskal-Wallis
test; P- values of <0.05 were considered significant. Kendal-
l's tau correlation coefficient between vascular perfusion and
tumour regrowth time was calculated from the group means
for each photosensitiser; cured tumours were also taken into
account in assessing significance.
The association of the different treatments with the re-
growth time was analysed using non-parametric survival
analysis methods. To study simultaneously the influence of
photosensitiser, light and MMC on regrowth time, a Wilcox-
on's proportional hazard model was adjusted using a step-
Table III Vascular perfusion (% g-' tissue) in control groups of
tumours or kidneys
Treatment Tumour Kidney
Untreated control 2.2 ± 0.2 23.5 ± 3.2
m-THPC (0.3 mg kg-') 1.9 ± 0.2 20.4 ± 1.0
BCA (20 mg kg-') 1.8 ± 0.2 24.6 ± 2.6
Light alone (A=652 nm: 1.9 ± 0.3 30.3 ± 2.5a
30J cm-')
Light alone (A=750 nm: 0.8 ± 0.2b 19.9 ± 2.6
200 J cm-')
aSignificantly different from control group (P<0.05).
bSignificantly different from control group (P< 0.02).
wise procedure. The Breslow test (generalised Wilcoxon test)
was applied to compare PDT with or without MMC. The
statistical package BMDP module 2L was used.
Results
The tumour perfusion data are analysed as 86Rb counts per
gram of tissue, expressed as a percentage of the injected
activity (minus residual activity in the tail resulting from
leakage at the injection site) (Figure 1 and Table III). This
gives a measure of the proportion of the cardiac output
supplying that tissue. Light-alone (fibre insertion with light
a
Light dose (J cm-')
L-
0 b =3
cr
1
5
[~~~~~~~~~T ", "
,~~~~~~.
-10 10 30 50 70 90 110 130
Time after illumination (h)
Figure 1 (a) Relative perfusion of the RIFI tumours 5 min after
illumination with different light doses given 24 h after 0.15 (*)
and 0.3 (V) mg kg-' m-THPC or 15min after 20mg kg' BCA
(0). (b) Effect of PDT (30 J cm-') at 24 h after 0.15 (l) and 0.3
(V)mgkg-' m-THPC or 15min after 20mgkg-' BCA (0) on
relative perfusion at increasing times after illumination. Control
values (shown at 0 J cm'-I light dose) represent drug alone
tumour perfusion. Perfusion after Photofrin PDT (previously
published results; Van Geel et al., 1994) are also shown with the
dashed lines. Values are mean ± s.e.m. of 4-6 mice per
group.
Table IV Tumour survival parameters control groups
Viable cells g-' Plating Clonogenicity Surviving
tumour tissuea Percent efficiencya Percent (clonogenic cellsg-' fraction
Treatment (x 107) control (M/0) control tumour)a.b ( X 107) (%)
Untreated control 15.7 2.4c 100 33.8 4.3 100 5.4± 1.35 100
Fibre control 7.7 ± 2.6 49 21.5 ± 2.4 64 1.6 0.49 30
Light control 9.4 0.6 60 25.4 4.2 75 2.4 0.45 44
(A =630 nm)
Light control 9.8 + 1.1 62 24.1 ± 2.3 71 2.4 0.47 44
(1 =652 nm)
m-THPC 9.1 ± 1.7 58 27.1 ± 6.1 80 2.8 ± 0.96 52
(0.15 mg kg-')
Photofrin (10mgkg-') 11 ± 2.1 70 36.8 5.0 109 3.6 ± 0.47 67
MMC alone (24 h)d 7.4 ± 2.6 47 0.4± 0.2d 1 0.04 ± 0.02e 0.7
aMeans ± s.e.m. bCell yield x plating efficiency. cThe percentage of dead cells stained with trypan blue was 5%.
dMice were sacrificed 24 h after MMC injection. eSignificantly different from control group (P< 0.05).
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treatment) and drug-alone controls were also included for
both sensitisers. Both m-THPC and BCA alone caused small
non-significant decreases in tumour perfusion. Illumination
with 30 J cm-' 652 nm light also caused a small, non-
significant decrease in tumour perfusion. The vascular per-
fusion did decrease significantly after light alone with the
illumination wavelength and set-up used for the BCA
experiments, probably caused by the larger outer diameter of
the fibre tip used for these illuminations. m-THPC PDT and
BCA PDT caused a light dose-dependent reduction in per-
fusion which was very similar to that seen after Photofrin-
PDT (Van Geel et al., 1993) (Figure la). For m-THPC (0.15
and 0.3 mg kg- ) and BCA PDT the vascular perfusion
decreased significantly from approximately 1.8% of the
injected dose in untreated tumours to ± 0.5% at 5 min after
100-120 J cm-'. Subsequent experiments investigated the
influence of PDT on tumour perfusion at longer time inter-
vals of up to 5 days after 30 J cm-' illumination (Figure Ib).
The minimum perfusion was at 24 h for all photosensitisers,
but with m-THPC and BCA the decrease in perfusion from
5 min to 24 h was more pronounced than for Photofrin. No
vascular perfusion could be measured beyond 24 h after BCA
or 0.3 mg kg-' m-THPC since the tumorous tissue had been
destroyed. For Photofrin PDT at least 100 J cm-' was
required for the same decrease in vascular perfusion as seen
with BCA or m-THPC with 30 J cm-' (Van Geel et al.,
1994).
The measured values for mean tumour perfusion at 5 min
after PDT were compared with the mean regrowth time
achieved for the same drug and light treatments (separate
experiments). A light dose range of 15-120 J cm-' or
30-400 J cm-' was used for tumour regrowth studies for
m-THPC PDT and BCA PDT respectively. The Kendall's
tau correlation coefficient between tumour growth time and
perfusion was R = -0.80, -0.60, -0.73 and -0.67 respec-
tively for Photofrin (Van Geel et al., 1994) m-THPC (0.15 mg
kg-'), m-THPC (0.3 mg kg-') and BCA (20 mg kg-'). For all
tested photosensitisers there was an inverse linear relation-
ship between tumour regrowth time and vascular perfusion,
but for m-THPC and BCA the correlation was less
strong.
In vitro tumour cell survival after in vivo PDT
The correlation of vascular perfusion and regrowth time
suggested that for m-THPC a decrease in vascular perfusion
seemed to be less important for tumour response than for
Photofrin. Direct PDT-induced tumour cell death may there-
fore be more important for m-THPC than indirect vascular
effects. This hypothesis was tested in an in vivo/in vitro assay
in which the time course of cell death was determined by
progressively delaying the time of tumour excision after in
vivo treatment. For each experiment, three parameters were
recorded: total cell yield per gram of tumour tissue; plating
efficiency of recovered cells; and the product of cell yield and
plating efficiency, which defines the number of surviving
clonogens per gram of tumour. Light and drug doses were
chosen which resulted in similar regrowth times for the
different photosensitisers (0.15 mg kg-' m-THPC with
60J cm- gives 15.3 ± 1.2 days regrowth time; or I0mg kg-I
Photofrin with 150 J cm' gives 14.6 ± 1.3 days regrowth
time).
Table IV shows the tumour survival parameters for various
control groups. The percentage of dead cells after trypan
blue staining was 5% for the untreated control group. The
number of clonogens per gram of tumour fell to 30-44% of
untreated control values as a result of fibre insertion with or
without illumination. m-THPC or Photofrin alone reduced
the clonogens g-' to 52% and 67% of the control values
respectively. When m-THPC PDT or Photofrin PDT was
administered and tumour cell suspensions were made immed-
iately after treatment, a further reduction in cell yield and
plating efficiency was observed (Figure 2). This probably
resulted from direct cell death caused by PDT. There was no
significant difference in plating efficiency between the two
In
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Figure 2 Tumour cell survival kinetics following in vivo PDT as
a function of excision time. Photofrin PDT: 10 mgkg-', 150 J
cm-' (open symbols). m-THPC PDT: 0.15mgkg-', 6OJcm-'
(closed symbols). Squares: plating efficiency. Circles: yield of
viable cells-' g- tumour tissue. Triangles: clonogenic cells-' g-'
tumour. Data points represent group mean values ± s.e.
photosensitisers, but a small difference was found in cell yield
when the tumours were excised 1, 6 and 16 h after illumina-
tion, resulting in more clonogenic cells g-' tumour for m-
THPC. Excision of the tumours after 24 h showed similar
decreases in cell yield to 1% and plating efficiency to 40%
for both photosensitisers.
It was clear from tumour perfusion experiments that all
three photosensitisers induced a substantial reduction in per-
fusion for subcurative light doses. It has been suggested that
transient PDT-induced hypoxia could be exploited to
enhance the tumoricidal effects of bioreductive drugs which
are specifically toxic against hypoxic cells (Gonzalez et al.,
1986). The effect of Photofrin or m-THPC PDT in combina-
tion with MMC was therefore also tested in the in vivo/in
vitro experiments. MMC alone caused no more than a 4 day
delay in tumour regrowth in vivo and reduced the surviving
fraction to <1% when assayed by the in vivo-in vitro techni-
que 24 h after injection (Table V). Other experiments with
MMC alone showed a 0.34% ± 0.24% surviving fraction
when assayed 20 min after MMC injection. The unexpectedly
low surviving fractions, in relation to the modest 4 days
tumour regrowth time (Table II), may have been due to the
drug being carried over with the tumour into the dispersal
medium and causing additional cell killing (Twentyman,
1977). Untreated and MMC-treated tumour halves were
therefore combined and tested for this. The killing artifact
was apparently absent here, since the plating efficiency of the
mixture could be adequately predicted from the separate
plating efficiencies without invoking interactions. An alterna-
tive explanation is that cells are made sensitive to the killing
action of MMC during dispersal (the number of living cells
decreased from 93% control value to about 80%).
For Photofrin and m-THPC PDT in combination with
MMC, the 24h time point is reliable since the half-life of
MMC is 10-50 min under physiological conditions, therefore
no free drug will be present at this time. Cell survival
assessed 24h after equitoxic drug light schedules (15 days
regrowth time), was significantly lower after PDT in com-
bination with MMC than after PDT alone. Clonogenicities
for Photofrin and m-THPC PDT in combination with MMC
were 0.02% ± 0.003% and 0.3% ± 0.07% respectively. These
values are consistent with additive cell killing from MMC
and PDT.
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Tumour regrowth studies after PDT in combination with
MMC
Control experiments were performed to evaluate the individ-
ual effects of photosensitisers, MMC, light or fibre insertion
alone on tumour regrowth (Table II). A small but significant
increase in growth time occurred when the photosensitiser,
fibre and/or light alone was given. MMC alone also induced
a small, but significant, increase in tumour regrowth time.
The combination of MMC with m-THPC, BCA or illumina-
tion (652 nm) was not significantly different from MMC
alone.
BCA was tested in tumour regrowth studies in a concen-
tration of 10-30 mg kg-', given 15 min or 1 h before light
treatment (Figure 3). When BCA was given 15 min before
illumination, regrowth time was greater than with the 1 h
time interval. BCA in a concentration of 30 mg kg-' given
15 min before light treatment was too toxic (1/3 deaths). The
schedule of 20 mg kg-' given at 15 min before illumination
was therefore chosen for further studies. Figure 4 shows the
mean tumour regrowth times after the combined treatment of
PDT and MMC compared with m-THPC or BCA PDT
alone. The in vivo photosensitising ability of both drugs was
compared with previously published results for Photofrin
PDT with or without MMC (Baas et al., 1994; dashed lines
in Figure 4). m-THPC-mediated PDT alone (Van Geel et al.,
co
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1995) resulted in longer regrowth times and more cures than
Photofrin-mediated PDT, at much lower light doses (Figure
4, Table V). Reducing the time interval between m-THPC
and illumination from 1 day to 1 h did not increase tumour
growth delay (Figure 4), but more cures were seen at lower
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Figure 3 Tumour regrowth time for increasing doses of BCA
(10-30 mg kg- ) given 15 min (0) or 1 h (U) before illumination
with 150 J cm-'. For the 30 mg kg-' drug dose, one out of three
mice died at the 15 min interval (t). For the other groups there
were no deaths and values are mean tumour regrowth times ±
s.e.m. of six mice per group. Groups containing animals with
cured tumours are indicated by asterisks.
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Figure 4 Regrowth time of the RIFI tumour after PDT with
(closed symbols) or without MMC (open symbols) with increas-
ing light doses. m-THPC in the concentration 0.15 mg kg-' was
given 1 h (O) or 1 day (0) before illumination. m-THPC in a
concentration of 0.3 mg kg-' was given 1 day before illumination
and BCA in a concentration of 20 mg kg-' 15 min before illu-
mination. Previously published Photofrin data (Baas et al., 1994)
for regrowth time after PDT alone (- -) or with MMC (-)
are also indicated by the dashed lines. The data for m-THPC
PDT were previously published (Van Geel et al., 1994). Values
are mean ± s.e.m. of 6-10 mice per group. When no error bars
are visible they were smaller than the symbol.
Table V Number of cures per treatment group: photosensitiser was given 15 min, 1 h or I day before illumination
Light dose m-THPC (I h) m-THPC (I day) m-THPC (I day) BCA (15min)
(Jcm-') 0.15 mgkg-' 0.15 mgkg-' 0.3 mgkg' 20 mgkg-'
-MMCa +MMC -MMCc +MMC -MMC0 +MMC -MMC +MMC
0 0/8 0/8 0/8 0/17 0/14 0/15 0/6
15 - - - - 0/8 - - -
30 0/8 3/12 0/8 1/8 0/8 0/8 0/6 0/6
45 - 5/10 - - - 1/8 - -
60 1/8 2/10 0/8 2/8 0/8 3/8
75 - -
90 6/7b 3/8 3/8 4/8 7/8 - -
100 - - - - - - 0/6 0/6
120 5/9 - 1/8 4/8 3/8b _- -
150 - 0/8 - - 1/5 -
180 - - 1/8 - - - -
200 - - - - - - 5/6 1/6
240 - - - - - -
300 - - - - - - 3/6
400 - - - - - _ 2/5b
TCD50d (J cm') 93 ± 12 103.7 ± 18.5 124 ± 25 66.5 ± 6.2
aPreviously published (Van Geel et al., 1995). b12.5-20% deaths were found in these groups: only survivors are given in the
denominator. C<12.5% survivals. dLight dose required to cure 50% of the tumours. -, not determined.
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light doses (Table V). This time interval was, however, also
more toxic and led to deaths in combination with high light
doses. BCA PDT gave approximately the same tumour re-
growth delay as Photofrin PDT, but cures were found at
light doses of 150 J cm-', whereas for Photofrin PDT no
cures were found below 400 J cm'- (Table III).
After PDT alone, a plateau in regrowth time was reached
at 15-20 days. Some cures were found at higher light doses,
but there was no further increase in regrowth time. This may
be indicative of a PDT-resistant cell population, and PDT in
combination with MMC may overcome this problem. m-
THPC PDT in combination with MMC resulted in highly
significant increases in tumour response compared with PDT
alone for both drug concentrations and all light doses tested
for the 1 h and 1 day interval. MMC given immediately after
illumination (m-THPC PDT) was equally effective (24.5 ±
1.71 days regrowth time, 5/8 cures) as MMC given 15 min
before illumination (25.6 ± 1.69 days regrowth time, 3/8
cures). The light dose for 50% cures (TCD50) decreased from
124 ± 25 J cm' at 1 day after 0.3 mg kg-' m-THPC to
67 ± 6J cm-' for 0.3 mg kg-' in combination with MMC. No
TCDs, could be determined for 0.15 mg kg-' m-THPC 1 day
before illumination, but for the combination mTHPC
(0.15 mg kg-') with MMC the TCD50 was 104 ± 19 J cm-'.
The combination BCA PDT with MMC did not result in a
significant increase in tumour regrowth time or more cures
compared with BCA PDT alone when the sensitiser was
given 15 min before illumination. When BCA was injected
1 h before illumination (100 J cm- 1), however, the combina-
tion with MMC resulted in a significant increase in regrowth
time (from 12.9 ± 1.1 to 23.1 ± 2.9 days). No TCD50 could be
calculated for BCA PDT with or without MMC. Previously
published results have demonstrated that the TCD5O for
Photofrin-mediated PDT decreases from 731 ± 70 J cm'l for
PDT alone to 319 ± 49 J cm' when Photofrin PDT is given
in combination with MMC (Baas et al., 1994).
Discussion
PDT can cause cell death both by direct disruption of the
cellular membranes and organelles, e.g. mitochondria (Gross-
weiner, 1984), and by damage to the tumour vasculature
leading to secondary tumour cell death (Castellani et al.,
1963; Bugelski et al., 1981; Star et al., 1986). Using the 86Rb
technique (Van Geel et al., 1994), we have shown that non-
curative doses of m-THPC and BCA PDT decrease vascular
perfusion in the RIFI tumour for a period of at least 24 h.
This decrease was more pronounced for m-THPC and BCA
PDT than for Photofrin PDT for the same light dose. In
previous experiments (Van Geel et al., 1994) we found an
inverse relationship between vascular perfusion after sub-
curative Photofrin PDT and regrowth time in the RIFI
tumour. An inverse correlation was also found for m-THPC
and BCA PDT, but the correlation was much less pro-
nounced possibly indicating a greater component of direct
tumour cell killing for these sensitisers.
With in vivo/in vitro experiments we have tried to separate
the direct tumour cell killing (excision immediately after
treatment) from indirect vascular effects (delayed excision
and assessment of clonogenicity) as previously described by
Henderson et al. (1985). Delivery of in vivo PDT treatment
did not immediately lead to a reduction in tumour clono-
genicity for either m-THPC or Photofrin, implying that the
phototoxic effect on the tumour cells was not sufficient to
render them non-reproductive. It was necessary for the
tumours to remain in situ after completion of treatment for
tumour cell death to occur. Similar observations were made
by Henderson et al. (1985), who found that when cells were
excised and plated immediately after Photofrin PDT there
was no reduction of cell survival in vitro, although in vivo
tumour necrosis was observed after the doses used. When the
cells were left in situ for 24 h and then plated, the in vitro
survival was markedly reduced. The authors interpreted this
effect as evidence of delayed secondary tumour cell death due
to vascular damage and induced hypoxia, with little direct
toxicity. Our results indicated that clonogenicity decreases
were slightly, but not significantly, slower after m-THPC
PDT than for Photofrin. These findings do not support the
original hypothesis of greater direct tumour cell killing after
m-THPC PDT. This suggests that tumour destruction in vivo
involves additional factors other than direct tumour cell kill-
ing or damage to the vasculature, e.g. host-related factors.
A potential way of improving the tumoricidal effects of
PDT is to exploit the induced chronic hypoxia by combining
PDT with bioreductive drugs. Since bioreductive drugs are
activated to a cytotoxic product under hypoxic conditions,
their activity can be enhanced in vivo when used together
with treatments that enhance the depth or duration of
hypoxia in solid tumours. The first reports of PDT combined
with bioreductive drugs were from Gonzalez et al. (1986).
They found that a large increase in the regrowth time of
Dunning rat tumours was seen when misonidazole was
administered 20 min before or after illumination. Several
other investigators (Bremner et al., 1992; Baas et al., 1994)
have subsequently demonstrated a clear advantage for the
combined treatment of PDT plus various bioreductive drugs
vs. PDT alone.
PDT in combination with MMC gave a significant de-
crease in the number of clonogens g-' tumour in our in
vivo/in vitro experiments at 24 h after Photofrin- or m-THPC-
mediated PDT, mainly caused by a large decrease in plating
efficiency. In vivo tumour response experiments also demon-
strated that MMC given 15 min before PDT substantially
increased tumour regrowth time. Light doses could be reduc-
ed by a factor of 2 in combination with MMC for equivalent
effects compared with PDT alone for m-THPC PDT. These
results were similar to those previously reported for Photo-
frin-mediated PDT in combination with MMC. For m-THPC
PDT, however, MMC given after illumination was equally as
effective as MMC before illumination. This is different from
the results found with Photofrin PDT (Baas et al., 1994),
where the maximum benefit from the combination MMC +
PDT is obtained when the drug is given before illumination.
This difference may be due to the higher light dose
(400 J cm- ') required for effective tumour treatment with
Photofrin-mediated PDT. These light doses require 68 min
for delivery, by which time vascular perfusion probably
inhibits the access of MMC into the tumour (Van Geel et al.,
1994). For BCA PDT in combination with MMC, no in-
crease in tumour response was found compared with BCA
PDT alone when the sensitiser was administered at 15 min
before illumination. This may be explained by the fact that
MMC was injected at the same time as BCA. The dispersion
of BCA through the tumour may not be optimal at such a
short time interval, resulting in fewer BCA PDT-damaged
tumour cells being triggered to die by the action of MMC.
When the BCA was injected I h before illumination, MMC
did increase the PDT response.
Our experiments demonstrate that there is a reduced vas-
cular perfusion in the RIFI tumour after various doses of
m-THPC or BCA PDT, which persist for at least 24 h. No
distinction could be made between m-THPC and Photofrin
PDT when looking at direct tumour cell death and secondary
cell death in our in vivo/vitro assay. Hypoxia induced by
vascular damage can be exploited by the combination of
m-THPC PDT and MMC. Enhancement of the tumoricidal
effect means that lower drug and light doses can be used for
equal tumour effects. The use of lower photosensitiser doses
would reduce the skin photosensitisation associated with
PDT in the clinic. The advantage of lower light doses is that
treatment times are reduced, which is favourable particularly
for less efficient sensitisers. This would enable a more wide-
spread use of PDT, with treatment of larger surface areas
within acceptable time limits.
349Mechanisms for optimising PDT
Wv IPJ van Geel etal
350
Acknowledgements
We are grateful to Dr A Begg and Dr P Baas for many helpful
discussions and to Dr 0 Dalesio for the statistical analysis. We
thank Quadra Logic Technologies, Vancouver, Canada, for giving us
Photofrin, and Scotia, Guildford, UK, for supplying us with m-
THPC. The present work was supported by the Dutch Cancer
Society, Project NKI 91-05.
References
BAAS P., OPPELAAR H, STAVENUITER M, ZANDWIJK N AND STE-
WART FA. (1993). Interaction of the bioreductive drug (SR4233)
and photodynamic therapy using Photofrin II in a mouse tumour
model. Int. J. Radiat. Biol. Oncol. Phys., 27, 665-670.
BAAS P, OPPELAAR H, MICHIELSEN C, ZANDWIJK N AND STE-
WART FA. (1994). Enhancement of interstitial photodynamic
therapy by mitomycin C and E09 in a mouse tumour model. Int.
J. Cancer, 56, 880-885.
BEST JA, SCHUITMAKER JJ, DUBBELMAN TMAR, VAN DER POEL
CJ, FAKKEL J. (1993). Near infrared diode laser for photo-
dynamic tumour therapy using BCA. Lasers Med. Sci., 8,
157-162.
BREMNER JCM, ADAMS GE, PEARSON JK, SANSOM J, STRATFORD
IJ, BEDWELL J, BOWN SG AND PHILIPS D. (1992). Increasing the
effect of photodynamic therapy on the RIF1 murine sarcoma,
using the bioreductive drugs RSU1069 and RB6145. Br. J.
Cancer, 66, 1070-1076.
BUGELSKI PJ, PORTER CW AND DOUGHERTY TJ. (1981). Auto-
radiographic distribution of hematoporphyrin in normal and
tumour tissue of the mouse. Cancer Res., 41, 4606-4612.
CASTELLANI A, PACE GP AND CONCIOLI M. (1963). Photodynamic
effect of haematoporphyrin on blood microcirculation. J. Pathol.
Bacteriol., 86, 99-102.
DOUGHERTY TJ, COOPER MT AND MANG TS. (1990). Cutaneous
phototoxicity occurrences in patients receiving Photofrin. Lasers
Med. Surg., 10, 485-488.
VAN GEEL IPJ, OPPELAAR H, OUSSOREN Y AND STEWART FA.
(1994). Changes in perfusion of mouse tumours after photo-
dynamic therapy. Int. J. Cancer, 56, 224-228.
VAN GEEL IPJ, OPPELAAR H, OUSSOREN Y AND STEWART FA.
(1995). Photosensitizing efficacy of mTHPC-PDT compared to
Photofrin-PDT in the RIFI mouse tumour and normal skin. Int.
J. Cancer, 60, 388-394.
GONZALEZ S, ARNFIELD MR, MEEKER BE, TULIP J, LAKEY WH
AND CHAPMAN JD. (1986). Treatment of Dunning R3327-AT
rat prostate tumours with photodynamic therapy in combination
with misonidazole. Cancer Res., 46, 2858-2862.
GROSSWEINER LI. (1984). Membrane photosensitisation by hema-
toporphyrin and hematoporphyrin derivative. In Photofrin
Localization and Treatments of Tumours, Gomer CJ and Doraian
DR. (eds) pp. 391-404. Alan R. Liss: New York.
HENDERSON BW, STEPHEN MW, MANG TS, POTTER WR, MALONE
PB AND DOUGHERTY TJ. (1985). Tumour destruction and
kinetics of tumour cell death in two experimental mouse tumors
following photodynamic therapy. Cancer Res., 45, 572-576.
VAN LEENGOED HLLM, SCHUITMAKER JJ, VAN DER VEEN N, DUB-
BELMAN TMAR, STAR WM. (1993). Fluorescence and photo-
dynamic effects of bacteriochlorin a observed in vivo in 'sand-
wich' observation chambers. Br. J. Cancer, 67, 898-903.
MOORE RB, CHAPMAN JD, MERCER JR, MANNAN RH, WIEBE LI,
MCEWAN AJ, MCPHEE MS. (1993). Measurement of PDT-induced
hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin
arabinoside. J. Nucl. Med., 34, 405-413.
RIS HB, ALTERMATT HJ, INDERBITZI R, NACHBUR B, STEWART
JCM, WANG Q, LIM CK, BONNET R, BERENBAUM MC AND
ALTHAUS U. (1991). Photodynamic therapy with chlorins for
diffuse malignant mesothelioma: initial clinical results. Br. J.
Cancer, 64, 1116-1120.
RIS HB, ALTERMATT HJ, NACHBUR B, STEWART CM, WANG Q,
LIM CK, BONNET R AND ALTHAUS U. (1993). Effect of drug-
light interval on photodynamic therapy with metatetrahydroxy-
phenylchlorin in malignant mesothelioma. Int. J. Cancer, 53,
141-146.
SCHUITMAKER JJ, BEST JA, DELFT JL, DUBBELMAN TMAR, OOS-
TERHUIS JA AND WOLFF-ROUENDAAL D. (1990). Bacterio-
chlorin a, a new photosensitizer in photodynamic therapy: In
vivo results. Invest. Opthalmol. Vis. Sci., 31, 1444-1450.
STAR WM, MARIJNISSEN HPA, BERG-BLOK AE, VERSTEEG JAC,
FRANKEN KAP AND REINHOLD HS. (1986). Destruction of rat
mammary tumour and normal tissue microcirculation by
hematoporphyrin derivative photoirradiation observed in vivo in
sandwich observation chambers. Cancer Res., 46, 2532-2540.
TWENTYMAN PR. (1977). An artefact in clonogenic assays of
bleomycin cytotoxicity. Br. J. Cancer, 36, 642-644.
TWENTYMAN PR, BROWN JM, GRAY JW, FRANKA AJ, SCOLES MA
AND KALLMAN RF. (1980). A new mouse tumour model system
(RIF-1) for comparison of end-point studies. J. Natl. Cancer
Inst., 64, 594-604.